Metro Infectious Disease Consultants

What Metro Infectious Disease Consultants does

Metro Infectious Disease Consultants (MIDC) is a physician-owned private practice infectious disease group founded in 1994 in the Chicago area by six physicians (Russ Petrak, Bob Fliegelman, Dave Hines, Dan Hirsch, Rodica Dumitru, and Dave Waitley) and financed initially through personal contributions and home-secured debt. Itself described as the nation's largest ID private practice, MIDC today employs more than 100 ID Fellowship-trained physicians, 57 advanced practice providers, 80 infusion nurses, and 20 ID pharmacists, operating across 7+ U.S. states (Illinois, Alabama, Arizona, California, Georgia, Kansas, Michigan, Missouri) with roughly 28 office locations and 20+ Metro Infusion Center sites.

The group's core offerings span inpatient and outpatient ID consultation, outpatient parenteral antibiotic therapy (OPAT), biologic infusion services covering agents such as Remicade, Tysabri, IVIG, Actemra, Benlysta, Cimzia, Orencia, Prolia, Rituxan, Xolair, Entyvio, Krystexxa, Nulojix, Fabrazyme, and colony-stimulating factors, HIV/AIDS and STD treatment, ID Telemedicine (12,000+ encounters in 2023), and a Hospital Avoidance Program that delivers same-day outpatient care for acute infections such as cellulitis, osteomyelitis, abscesses, and UTIs. CRNI-certified nurses manage infusion delivery, and the practice operates an iqHealth-based patient portal and a Metro-Dash employee portal.

Revenue is generated primarily through professional-fee billing to insurance carriers (Aetna, Anthem, BCBS, Cigna, Coventry, Humana, Multiplan, PHCS, PriorityHealth, UHC, Medicare, and others); the practice explicitly does not charge facility fees, lowering patient out-of-pocket costs relative to hospital settings. Supplementary revenue streams include hospital contracts for infection prevention (IP) and antibiotic stewardship program (ASP) management, biologic infusion services, and clinical research via the affiliated Metro Research Center. Centralized back-office functions (billing, collections, scheduling, HR, contracting, EMR, capital) are provided by Innovative Ventures, a management services organization led by MIDC's Managing Partner Russell Petrak, supporting both the practice and potentially other ID groups. Go-to-market is referral-driven — dedicated referral phone and fax lines for physicians, hospital partnerships, and direct patient bookings — supplemented by a recruitment-oriented content marketing effort targeting ID physicians with claims of 1.5–3x national-average ID compensation.

Name

Metro Infectious Disease Consultants

Legal name

Metro Infectious Disease Consultants

Website

https://midcusa.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Short description

Metro Infectious Disease Consultants, the nation's largest private ID physician group, operates across 7+ U.S. states with 100+ ID physicians. It delivers ID consultation, OPAT, biologic infusions, telemedicine, and a Hospital Avoidance Program via referral-based outpatient offices.

Ownership category

akta.pro rank

Product category

Infectious Disease Healthcare Services

NAICS

Offices of Physicians (except Mental Health Specialists) (621111), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Pediatric Infectious Disease (HLAKAGAE)

Keywords

• Infectious disease care
• Outpatient antibiotic therapy
• Biologic infusion services
• Hospital avoidance program
• Telemedicine consultation

Headquarters

HQ city

Avondale

HQ country

United States

HQ region

North America

Offices29 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D

Revenue model

1. Telemedicine Consultation Services: Inpatient and outpatient telemedicine consultation services provided to hospitals for infection prevention and antibiotic stewardship program management. In 2023, physicians saw over 12,000 telemedicine encounters.
2. Outpatient Parenteral Antibiotic Therapy (OPAT): Outpatient antibiotic therapy delivered at each office location, allowing physicians to benefit financially from professional fee generation.
3. Biological Infusion Services: Infusion therapies including colony-stimulating factors, Fabrazyme, IV steroids, Actemra, Benlysta, Cimzia, Orencia, Prolia, Remicade, Rituxan, Tysabri, Xolair, Entyvio, Krystexxa, Nulojix, and intravenously administered immunoglobulin (IVIG).
4. Contract Support Services: Revenue from contractual support arrangements with healthcare facilities for ID consultation and management services.
5. Educational Lectures: Physicians benefit from educational lectures and related professional activities within the private practice model.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Core offering

Metro Infectious Disease Consultants (MIDC) is a physician-owned private practice that delivers infectious disease consultation, outpatient parenteral antibiotic therapy (OPAT), and biologic infusion services through owned clinic locations across seven U.S. states. The practice operates the Hospital Avoidance Program for same-day outpatient treatment of acute infections, provides 24/7 ID telemedicine consultation to hospitals for infection prevention and antibiotic stewardship, and administers a wide range of infusible pharmaceuticals (Remicade, Tysabri, IVIG, and others) through CRNI-certified nurses.

Product overview

Metro Infectious Disease Consultants operates as a platform of affiliated healthcare brands providing infectious disease care, infusion therapies, and specialty services. The core offering is MIDC's infectious disease physician services, supported by Metro Infusion Center (infusion therapies), Metro Rheumatology Associates (rheumatologic care), Metro Neurologic Associates (neurologic care), and Metro Research Center (clinical research). Service modules include the Hospital Avoidance Program for acute conditions, Outpatient Antibiotic Therapy (OPAT), Biological Infusion Services, ID Telemedicine consultations, and HIV/AIDS/STD treatment services. The organization spans 7 states with over 100 ID physicians and multiple office locations.

Differentiator

Problem solved

Functional benefit

Products and services

• Metro Infusion Center State-of-the-art intravenous therapy centers co-located within MIDC clinical offices that deliver all infusible agents including Remicade, Tysabri, Immunoglobulin, and antibiotics. CRNI-certified nurses manage IV line placement, maintenance, drug administration, and patient education. Over 20 locations nationally, with 10 in the Chicagoland area.
• Hospital Avoidance Program Rapid-response evaluation and treatment program providing same-day outpatient service for acute conditions such as cellulitis, osteomyelitis, abscesses, and urinary tract infections, enabling patients to receive inpatient-level care in outpatient settings without hospital facility fees.
• Outpatient Antibiotic Therapy (OPAT) Outpatient parenteral antibiotic therapy program allowing patients to receive IV antibiotics in non-hospital settings, eliminating inpatient stay costs and featuring 24/7 physician, nursing, pharmacy, and laboratory support.
• Biological Infusion Services Comprehensive infusion services for biologic therapies including colony-stimulating factors, Fabrazyme, IV steroids, Actemra, Benlysta, Cimzia, Orencia, Prolia, Remicade, Rituxan, Tysabri, Xolair, Entyvio, Krystexxa, Nulojix, intravenously administered immunoglobulin (IVIG), and Total Parenteral Nutrition, administered by CRNI-certified nurses for pediatric and adult patients.
• ID Telemedicine Telemedicine consultation and management services for infectious disease, infection prevention (IP), and antibiotic stewardship programs (ASP) delivered to hospitals, with ID Fellowship-trained physicians dedicated to specific hospitals for consistent ID care. Over 12,000 telemedicine encounters were completed in 2023.
• Metro Rheumatology Associates (MRA) Specialty clinic for diagnosis and treatment of rheumatic diseases including arthritis, chronic pain, and joint problems, offering in-house clinical and laboratory services, bone density testing, X-ray, and FDA-approved rheumatologic pharmaceuticals including Remicade infusions. Available at MIDC's Crestwood, Burr Ridge, and Northside Chicago offices.
• Metro Neurologic Associates (MNA) Specialty clinic for diagnosis and treatment of neurologic diseases including multiple sclerosis, stroke, neuropathy, and other neurological conditions, operating through the MIDC Crestwood office with in-house clinical and laboratory evaluations.
• Metro Research Center Affiliated research center conducting clinical research in infectious diseases and related therapeutic areas, supporting clinical research revenue and physician participation in research activities.
• HIV/AIDS and STD Treatment Services Infectious disease treatment and consultation for HIV/AIDS, sexually transmitted diseases, and other infectious diseases provided in outpatient care settings across MIDC office locations.

Quantifiable outcome

• Over 12,000 telemedicine encounters in 2023
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Metro Infusion CentercoreStrategic or Co-development PartnerMetro Infusion Centers are located within the clinical offices of Metro Infectious Disease Consultants, providing state-of-the-art intravenous therapies including Remicade, Tysabri, Immunoglobulin, and antibiotics. CRNI-certified nurses manage all aspects of treatment. Over 20 locations nationally with 10 in Chicagoland.
• Metro Rheumatology Associates (MRA)coreStrategic or Co-development PartnerMetro Rheumatology Associates specializes in diagnosis and treatment of rheumatic diseases including arthritis, chronic pain, and joint problems. Offers in-house clinical and laboratory services, bone density testing, X-ray, and FDA-approved rheumatological pharmaceuticals including Remicade infusions. Available at Crestwood, Burr Ridge, and Northside Chicago offices.
• Metro Neurologic Associates (MNA)coreStrategic or Co-development PartnerMetro Neurologic Associates specializes in diagnosis and treatment of neurologic diseases including multiple sclerosis, stroke, neuropathy, and other issues. Operates through the Metro Infectious Disease Consultants Crestwood office with in-house clinical and laboratory evaluations.
• Metro Research CentercoreStrategic or Co-development PartnerAffiliated research center that conducts clinical research in infectious diseases, supporting the group's research revenue stream and allowing physicians to benefit from clinical research activities.
• Hospitals (Telemedicine and Hospital Avoidance Program)coreChannel Partner/ Reseller/ DistributorID Fellowship-trained physicians dedicated to specific hospitals for consistent ID care. Active collaboration within MIDC including ID pharmDs and providers to optimize antibiotic usage. Hospitals benefit from reduced admissions through Hospital Avoidance Program and improved antibiotic stewardship outcomes.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ID Care: ID Care is one of the largest privately-held infectious disease specialty physician practices in the U.S., providing ID consultation, OPAT, infusion, and travel medicine across multiple New Jersey locations. Directly comparable to MIDC in scale and service mix.
• Carolina Infectious Disease Specialists: Multi-physician ID group serving North and South Carolina with hospital consultation, OPAT, and HIV care. Closely mirrors MIDC's physician-owned specialty practice model and outpatient-focused service offering.
• Infectious Disease Associates of Broward County: Established multi-physician ID specialty group in Florida delivering ID consultation, OPAT, and infusion services. Comparable to MIDC as a regional ID private practice with similar revenue mix and referral dynamics.

Broad incumbents

• Option Care Health: Largest independent provider of home and alternate-site infusion services in the U.S., publicly traded and operating nationally. Overlaps with MIDC's OPAT and biologic infusion services, though Option Care focuses on home-based rather than office-based delivery.
• Coram CVS Specialty Infusion Services: CVS Health subsidiary providing home infusion, specialty pharmacy, and OPAT administration across the U.S. Competes with MIDC on the infusion and OPAT revenue streams, but operates at vastly larger national scale under a parent health system.
• Privia Health: Public physician practice platform serving multi-specialty groups across more than 30 states with practice management, value-based care, and population health infrastructure. Comparable in operating model (multi-state physician-led practice platform) and infrastructure outsourcing, though much broader in specialty scope.
• US Anesthesia Partners: PE-backed multi-state physician specialty group platform (anesthesia) operating through a clinic partnership / management services structure analogous to MIDC's Innovative Ventures MSO arrangement. Compares on platform consolidation, MSO back-office, and physician-recruitment strategy rather than clinical specialty.

Emerging players

• Vivo Infusion: Multi-site ambulatory infusion center operator offering biologic infusion services in physician-office and standalone settings. Competes directly with MIDC's Metro Infusion Center brand for biologic infusion referrals in overlapping geographies.
• PURE Infusion Suites: Operates a network of standalone ambulatory infusion suites focused on patient comfort and biologic therapy administration. Direct partial-overlap competitor to Metro Infusion Center for biologic and autoimmune infusion referrals.

Others

• Sound Physicians: National physician services organization providing acute care, hospital medicine, critical care, and ID-focused program support including telemedicine antimicrobial stewardship to hospitals. Comparable through its hospital-facing ASP/IP telemedicine service line and physician group management model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/MIDCUSA

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metro Infectious Disease Consultants